A5100388227- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Animal Virus Infections Studies
- SARS-CoV-2 detection and testing
- Viral gastroenteritis research and epidemiology
- Monoclonal and Polyclonal Antibodies Research
- Influenza Virus Research Studies
- vaccines and immunoinformatics approaches
- Bacillus and Francisella bacterial research
- Bacteriophages and microbial interactions
- Immunotherapy and Immune Responses
- Viral Infections and Immunology Research
- Virus-based gene therapy research
- Corneal surgery and disorders
- Long-Term Effects of COVID-19
- Immune Cell Function and Interaction
- Vaccine Coverage and Hesitancy
- Respiratory viral infections research
- Mosquito-borne diseases and control
- COVID-19 diagnosis using AI
- Microbial Inactivation Methods
- Intraocular Surgery and Lenses
- COVID-19 epidemiological studies
- Plant Virus Research Studies
- Viral Infections and Outbreaks Research
Fudan University
2020-2025
AstraZeneca (United States)
2025
Huashan Hospital
2020-2025
Jiaxing University
2025
Sichuan University
2022-2025
West China Hospital of Sichuan University
2022-2025
National Institute of Allergy and Infectious Diseases
2013-2024
National Institutes of Health
2014-2024
Beijing Chao-Yang Hospital
2023-2024
Capital Medical University
2023-2024
Vaccines to prevent coronavirus disease 2019 (Covid-19) are urgently needed. The effect of severe acute respiratory syndrome 2 (SARS-CoV-2) vaccines on viral replication in both upper and lower airways is important evaluate nonhuman primates. Nonhuman primates received 10 or 100 μg mRNA-1273, a vaccine encoding the prefusion-stabilized spike protein SARS-CoV-2, no vaccine. Antibody T-cell responses were assessed before upper- lower-airway challenge with SARS-CoV-2. Active genomes...
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies key class of therapeutics that may bridge widespread vaccination campaigns offer treatment solution in populations less responsive to vaccination. Here, we report high-throughput microfluidic screening antigen-specific B cells led the identification LY-CoV555 (also known as bamlanivimab), potent anti-spike...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibodies (mAbs) can reduce the risk of hospitalization from disease 2019 (COVID-19) when administered early. However, SARS-CoV-2 variants concern (VOCs) have negatively affected therapeutic use some authorized mAbs. Using a high-throughput B cell screening pipeline, we isolated LY-CoV1404 (bebtelovimab), highly potent spike glycoprotein receptor binding domain (RBD)-specific antibody. potently neutralizes...
The emerging new VOC B.1.1.529 (Omicron) variant has raised serious concerns due to multiple mutations, reported significant immune escape, and unprecedented rapid spreading speed. Currently, studies describing the neutralization ability of different homologous heterologous booster vaccination against Omicron are still lacking. In this study, we explored immunogenicity COVID-19 breakthrough patients, BBIBP-CorV group BBIBP-CorV/ZF2001 SARS-CoV-2 pseudotypes corresponding prototype, Beta,...
Abstract The emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) as a cause severe disease highlights the need for effective approaches to CoV vaccine development. Efforts focused solely on receptor-binding domain (RBD) viral Spike (S) glycoprotein may not optimize neutralizing antibody (NAb) responses. Here we show that immunogens based full-length S DNA and S1 subunit protein elicit robust serum-neutralizing activity against several MERS-CoV strains in mice non-human...
Immune correlates of protection can be used as surrogate endpoints for vaccine efficacy. Here, nonhuman primates (NHPs) received either no or doses ranging from 0.3 to 100 μg the mRNA-1273 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. vaccination elicited circulating and mucosal antibody responses in a dose-dependent manner. Viral replication was significantly reduced bronchoalveolar lavages nasal swabs after SARS-CoV-2 challenge vaccinated animals most strongly...
Defenses against SARS-CoV-2 variants Our key defense the COVID-19 pandemic is neutralizing antibodies virus elicited by natural infection or vaccination. Recent emerging viral have raised concern because of their potential to escape antibody neutralization. Wang et al . identified four from early-outbreak convalescent donors that are potent 23 variants, including concern, and characterized binding spike protein severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Yuan examined...
The potential for future coronavirus outbreaks highlights the need to broadly target this group of pathogens. We used an epitope-agnostic approach identify six monoclonal antibodies that bind spike proteins from all seven human-infecting coronaviruses. All conserved fusion peptide region adjacent S2' cleavage site. COV44-62 and COV44-79 neutralize alpha- betacoronaviruses, including severe acute respiratory syndrome 2 (SARS-CoV-2) Omicron subvariants BA.2 BA.4/5, albeit with lower potency...
ABSTRACT Middle East respiratory syndrome coronavirus (MERS-CoV) causes a highly lethal pulmonary infection with ∼35% mortality. The potential for future pandemic originating from animal reservoirs or health care-associated events is major public concern. There are no vaccines therapeutic agents currently available MERS-CoV. Using probe-based single B cell cloning strategy, we have identified and characterized multiple neutralizing monoclonal antibodies (MAbs) specifically binding to the...
The rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (Omicron) variant and its resistance to neutralization by vaccinee convalescent sera are driving a search for monoclonal antibodies with potent neutralization. To provide insight into effective neutralization, we determined cryo-electron microscopy structures evaluated receptor binding domain (RBD) their ability bind neutralize B.1.1.529. Mutations altered 16% RBD surface, clustered on an ridge...
The Omicron variant of SARS-CoV-2 is raising concerns because its increased transmissibility and potential for reduced susceptibility to antibody neutralization. To assess the risk this existing vaccines, serum samples from mRNA-1273 vaccine recipients were tested neutralizing activity against compared neutralization titers D614G Beta in live virus pseudovirus assays. was 41-84-fold less sensitive than 5.3-7.4-fold when assayed with obtained 4 weeks after 2 standard inoculations 100 μg...
Bispecific antibodies targeting multiple regions of the SARS-CoV-2 spike protein comparably neutralize variants concern and wild-type virus.
Vaccination against SARS-CoV-2 provides an effective tool to combat the COVID-19 pandemic. Here, we combined antigen optimization and nanoparticle display develop vaccine candidates for SARS-CoV-2. We first displayed receptor-binding domain (RBD) on three self-assembling protein (SApNP) platforms using SpyTag/SpyCatcher system. then identified heptad repeat 2 (HR2) in S2 as cause of spike metastability, designed HR2-deleted glycine-capped (S2GΔHR2), S2GΔHR2 SApNPs. An antibody column...
Shanghai has been experiencing the Omicron wave since March 2022. Though several studies have evaluated risk factors of severe infections, analyses BA.2 infection and protective among geriatric people were much limited. This multicentre cohort study described clinical characteristics, assessed for infections. A total 1377 patients older than 60 enrolled, with 75.96% having comorbidities. The median viral shedding time hospitalization nine eight days, respectively. Severe critical associated...
Neuronal accumulation and spread of pathological α-synuclein (α-syn) fibrils are key events in Parkinson's disease (PD) pathophysiology. However, the neuronal mechanisms underlying uptake α-syn remain unclear. In this work, we identified FAM171A2 as a PD risk gene that affects aggregation. Overexpressing promotes fibril endocytosis exacerbates neurotoxicity pathology. Neuronal-specific knockdown expression shows protective effects. Mechanistically, extracellular domain 1 interacts with C...